NBEA
NBEA (Neurobeachin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Breast cancer, Colorectal cancer and 5 more.
Overview
Binds to type II regulatory subunits of protein kinase A and anchors/targets them to the membrane. May anchor the kinase to cytoskeletal and/or organelle-associated proteins.
Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.16, animal model 0.41, genetic association 0.62, somatic mutation 0.74). IntOGen calls it a driver in 14 cohorts (6 activating, 8 loss-of-function), covering Invasive Breast Carcinoma, Cervical Adenocarcinoma, Colon Adenocarcinoma, Colorectal Adenocarcinoma, Oesophageal Adenocarcinoma, Hepatocellular Carcinoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · NBEA (Neurobeachin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Breast cancer, Colorectal cancer and 5 more.
- 1 · What it is
NBEA (Neurobeachin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Breast cancer, Colorectal cancer and 5 more.
- 2 · What goes wrong in cancer
Binds to type II regulatory subunits of protein kinase A and anchors/targets them to the membrane. May anchor the kinase to cytoskeletal and/or organelle-associated proteins.
- 3 · How drugs use it
No product in this corpus aims at NBEA yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:7648 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q8NFP9 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000172915 (association with cancer (MONDO_0004992) 0.64; per-cancer scores at or above 0.5: ovarian cancer 0.51 (GraphQL API, CC0)); IntOGen NBEA (driver in 14 cohorts (Act 6, LoF 8); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Binds to type II regulatory subunits of protein kinase A and anchors/targets them to the membrane. May anchor the kinase to cytoskeletal and/or organelle-associated proteins. Location: Cytoplasm; Membrane (UniProt). Locus 13q13.3 (HGNC).
- Hepatocellular carcinoma: IntOGen driver in 3 cohorts (HCC)
- Breast cancer: IntOGen driver in 2 cohorts (BRCA)
- Colorectal cancer: IntOGen driver in 2 cohorts (COAD, COADREAD)
- Ovarian cancer: Open Targets association 0.51 with ovarian cancer (MONDO_0008170); IntOGen driver in 1 cohort (OVT)
- Cervical cancer: IntOGen driver in 1 cohort (CEAD)
- Oesophageal cancer: IntOGen driver in 1 cohort (ESCA)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 6 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 8 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"NBEA" OR ABSTRACT:"NBEA" OR TITLE:"neurobeachin" OR ABSTRACT:"neurobeachin" OR TITLE:"Neurobeachin" OR ABSTRACT:"Neurobeachin" OR TITLE:"KIAA1544" OR ABSTRACT:"KIAA1544" OR TITLE:"BCL8B" OR ABSTRACT:"BCL8B" OR TITLE:"FLJ10197" OR ABSTRACT:"FLJ10197") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NBEA, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCDH11
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Hepatocellular carcinoma, Breast cancer (all types).
- TargetKAT6A
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Breast cancer (all types), IntOGen.
- TargetNCOA2
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Breast cancer (all types), IntOGen.
- TargetEPHA3
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Breast cancer (all types), IntOGen.
- TargetNUMA1
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Breast cancer (all types), IntOGen.
- TargetZNF750
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Open Targets Platform.
- TargetHLA-B
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Cervical cancer, IntOGen.
- TargetNUTM1
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Ovarian cancer.